Table 1.

Secondary prevention with clinical endpoints using atorvastatin

Study	Population	Baseline mean LDL-C, mg/dL	N	Age range (mean), y	No. in elderly subgroup (%); Age cutoff, y	Intervention	Mean follow-up, y	Endpoint	RRR, %; (p)	ARR, %	NNT, %
											Older patients	Younger patients
Stable CHD
SAGE	CHD	148	893	65–85 (73)	893 (100); ≥65	Atorvastatin 80 mg vs pravastatin 40 mg	1	Major adverse cardiovascular events	29 (0.114)	3.1	32	–
								All-cause mortality	77 (0.014)	2.7	37	–
TNT, Elderly	CHD	96	10,001a	65–75 (70)	3809 (38);a ≥65	Atorvastatin 80 mg vs atorvastatin 10 mg	4.9b	Major cardiovascular events	19 (0.032)	2.3	35	26
IDEAL	CHD	121a	8888a	≤80 (61)a	3757 (42);a ≥65	Atorvastatin 80 mg vs simvastatin 20 mg	4.8b	Major cardiovascular events	13a (0.02)	1.7a	59a	–
								Nonfatal MI	17a (0.02)	1.2a	83a	–
Acute coronary syndrome
PROVE-IT, Elderly	ACS	96	4162a	≥70 (75)	730 (18);a ≥70	Atorvastatin 80 mg vs pravastatin 40 mg	2	Death, MI, UA, stroke, or revascularization after 30 days	40c (0.008)	8c	13c	43c
MIRACL, Elderly	ACS	121	3086a	≥65 (74)	1672 (54);a ≥65	Atorvastatin 80 mg vs placebo	0.3	Nonfatal MI, cardiac arrest with resuscitation, or recurrent symptomatic ischemia requiring hospitalization	14 (0.18)	2.9	34	40

Note: SAGE specifically and exclusively enrolled elderly participants.

^aData from parent study, includes subjects < and ≥65 years.

^bMedian.

^cElderly subjects who achieved LDL-C goal <70 mg/dl vs those who did not.

Abbreviations: LDL-C, low-density lipoprotein cholesterol; RRR, relative risk reduction; ARR, absolute risk reduction; NNT, number needed to treat; CHD, coronary heart disease; MI, myocardial infarction; UA, unstable angina; SAGE, Study Assessing Goals in the Elderly; TNT, Treating to New Targets; IDEAL, Incremental Decrease in End points through Aggressive Lipid lowering; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; MIRACL, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering.